Saud H Aldubayan, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Germ-Line Mutation | 11 | 2022 | 1858 | 1.170 |
Why?
|
Genetic Testing | 6 | 2021 | 3537 | 0.990 |
Why?
|
Testicular Neoplasms | 3 | 2021 | 799 | 0.910 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 491 | 0.690 |
Why?
|
Prostatic Neoplasms | 10 | 2021 | 11118 | 0.680 |
Why?
|
Propionic Acidemia | 1 | 2017 | 9 | 0.570 |
Why?
|
Carnitine | 1 | 2017 | 252 | 0.510 |
Why?
|
Inheritance Patterns | 1 | 2018 | 341 | 0.510 |
Why?
|
Arabs | 3 | 2023 | 187 | 0.500 |
Why?
|
Genetic Predisposition to Disease | 12 | 2022 | 17904 | 0.480 |
Why?
|
Metabolism, Inborn Errors | 1 | 2017 | 284 | 0.480 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2017 | 283 | 0.450 |
Why?
|
DNA Repair | 4 | 2020 | 2045 | 0.430 |
Why?
|
DNA Mutational Analysis | 2 | 2020 | 4111 | 0.420 |
Why?
|
DNA Mismatch Repair | 3 | 2019 | 428 | 0.360 |
Why?
|
Germ Cells | 4 | 2022 | 634 | 0.340 |
Why?
|
Fatty Acids | 1 | 2017 | 1808 | 0.320 |
Why?
|
Microsatellite Instability | 3 | 2024 | 716 | 0.320 |
Why?
|
Breast Neoplasms | 2 | 2023 | 21012 | 0.260 |
Why?
|
Melanoma | 2 | 2020 | 5709 | 0.250 |
Why?
|
Collagen Type VII | 1 | 2024 | 22 | 0.230 |
Why?
|
Epidermolysis Bullosa Dystrophica | 1 | 2024 | 29 | 0.230 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2023 | 107 | 0.210 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6935 | 0.190 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2021 | 117 | 0.180 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2020 | 37 | 0.180 |
Why?
|
Disease Management | 4 | 2018 | 2508 | 0.170 |
Why?
|
Neurofibromin 1 | 1 | 2020 | 190 | 0.160 |
Why?
|
Peroxisomal Disorders | 1 | 2018 | 12 | 0.160 |
Why?
|
Tamoxifen | 1 | 2023 | 965 | 0.160 |
Why?
|
Repressor Proteins | 2 | 2021 | 2986 | 0.150 |
Why?
|
Acute Disease | 3 | 2018 | 7237 | 0.150 |
Why?
|
Urea Cycle Disorders, Inborn | 1 | 2018 | 32 | 0.150 |
Why?
|
Maple Syrup Urine Disease | 1 | 2018 | 40 | 0.150 |
Why?
|
Pathology, Molecular | 1 | 2021 | 328 | 0.150 |
Why?
|
GTP Phosphohydrolases | 1 | 2020 | 517 | 0.140 |
Why?
|
Genetic Counseling | 1 | 2021 | 627 | 0.140 |
Why?
|
Multigene Family | 1 | 2019 | 1076 | 0.130 |
Why?
|
Genes, Neoplasm | 1 | 2018 | 370 | 0.130 |
Why?
|
Humans | 33 | 2024 | 761504 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5305 | 0.120 |
Why?
|
Breast | 1 | 2023 | 1967 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1092 | 0.110 |
Why?
|
Anemia, Sickle Cell | 1 | 2022 | 1063 | 0.110 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3639 | 0.110 |
Why?
|
Male | 18 | 2021 | 360804 | 0.110 |
Why?
|
Genomics | 4 | 2023 | 5821 | 0.110 |
Why?
|
Skin Neoplasms | 2 | 2024 | 5821 | 0.100 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2014 | 302 | 0.100 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1410 | 0.100 |
Why?
|
Mutation | 8 | 2023 | 30052 | 0.100 |
Why?
|
Marfan Syndrome | 1 | 2014 | 236 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2017 | 1186 | 0.100 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 380 | 0.100 |
Why?
|
Prostate-Specific Antigen | 1 | 2021 | 2469 | 0.100 |
Why?
|
Emergency Medicine | 2 | 2018 | 1198 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1801 | 0.090 |
Why?
|
Oxidation-Reduction | 1 | 2017 | 2231 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2020 | 2049 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2020 | 2057 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2021 | 2917 | 0.080 |
Why?
|
Aortic Aneurysm | 1 | 2014 | 648 | 0.080 |
Why?
|
Microfilament Proteins | 1 | 2014 | 1134 | 0.080 |
Why?
|
Carcinoma | 1 | 2019 | 2330 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 4026 | 0.080 |
Why?
|
Nuclear Proteins | 1 | 2021 | 5796 | 0.070 |
Why?
|
Disease Progression | 2 | 2021 | 13506 | 0.070 |
Why?
|
Actins | 1 | 2014 | 2050 | 0.070 |
Why?
|
MicroRNAs | 1 | 2022 | 3816 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4876 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3617 | 0.070 |
Why?
|
Genotype | 1 | 2021 | 12990 | 0.070 |
Why?
|
Female | 9 | 2023 | 392644 | 0.060 |
Why?
|
Critical Care | 1 | 2018 | 2696 | 0.060 |
Why?
|
Risk Factors | 3 | 2023 | 74206 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14666 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15266 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7856 | 0.060 |
Why?
|
Genome, Human | 1 | 2016 | 4425 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11742 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4652 | 0.050 |
Why?
|
Middle Aged | 8 | 2021 | 220895 | 0.050 |
Why?
|
Hemoglobin, Sickle | 1 | 2022 | 113 | 0.050 |
Why?
|
Glycosphingolipids | 1 | 2022 | 73 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5146 | 0.050 |
Why?
|
Saudi Arabia | 1 | 2022 | 210 | 0.050 |
Why?
|
beta-Globins | 1 | 2022 | 111 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5671 | 0.050 |
Why?
|
gamma-Globins | 1 | 2022 | 106 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8547 | 0.050 |
Why?
|
Neoplasms | 2 | 2021 | 22170 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 22176 | 0.050 |
Why?
|
Adult | 7 | 2021 | 221177 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 257 | 0.040 |
Why?
|
Fetal Hemoglobin | 1 | 2022 | 345 | 0.040 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 306 | 0.040 |
Why?
|
Young Adult | 4 | 2020 | 59243 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26125 | 0.040 |
Why?
|
Genetic Variation | 1 | 2014 | 6567 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 2 | 2021 | 4511 | 0.040 |
Why?
|
Cohort Studies | 2 | 2018 | 41487 | 0.040 |
Why?
|
Facies | 1 | 2018 | 222 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 345 | 0.040 |
Why?
|
Consanguinity | 1 | 2018 | 456 | 0.030 |
Why?
|
Aged | 6 | 2020 | 169289 | 0.030 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 223 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 4915 | 0.030 |
Why?
|
MutS Homolog 2 Protein | 1 | 2016 | 197 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2020 | 2115 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2021 | 1079 | 0.030 |
Why?
|
Ontario | 1 | 2016 | 398 | 0.030 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2020 | 974 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 662 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 2455 | 0.030 |
Why?
|
Teratoma | 1 | 2016 | 404 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2057 | 0.030 |
Why?
|
Prostatectomy | 1 | 2021 | 1824 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1520 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2865 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 899 | 0.030 |
Why?
|
DNA Damage | 1 | 2022 | 2446 | 0.020 |
Why?
|
History, 20th Century | 1 | 2020 | 2767 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1787 | 0.020 |
Why?
|
Leukocytes | 1 | 2020 | 2026 | 0.020 |
Why?
|
Multifactorial Inheritance | 1 | 2020 | 1387 | 0.020 |
Why?
|
Phenotype | 2 | 2020 | 16591 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1115 | 0.020 |
Why?
|
Family Health | 1 | 2016 | 1257 | 0.020 |
Why?
|
Pedigree | 1 | 2018 | 4542 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9606 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 2020 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2827 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 1779 | 0.020 |
Why?
|
Skin | 1 | 2024 | 4484 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3448 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9610 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2735 | 0.020 |
Why?
|
Heterozygote | 1 | 2016 | 2787 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2811 | 0.020 |
Why?
|
Cost of Illness | 1 | 2018 | 1936 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1745 | 0.020 |
Why?
|
Population Surveillance | 1 | 2018 | 2598 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1886 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2019 | 2449 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2244 | 0.020 |
Why?
|
Program Evaluation | 1 | 2016 | 2495 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2020 | 7594 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11076 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2018 | 3600 | 0.020 |
Why?
|
DNA Methylation | 1 | 2019 | 4398 | 0.020 |
Why?
|
Aging | 1 | 2024 | 8708 | 0.010 |
Why?
|
Mitochondria | 1 | 2016 | 3624 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20098 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9420 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2020 | 58976 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4740 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2021 | 80636 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15732 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7390 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9486 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12690 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16981 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 15936 | 0.010 |
Why?
|
Child | 2 | 2022 | 80153 | 0.010 |
Why?
|
Physicians | 1 | 2018 | 4591 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18395 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 29625 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21353 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23445 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 14031 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54425 | 0.010 |
Why?
|
Adolescent | 2 | 2016 | 88319 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20570 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2014 | 26198 | 0.010 |
Why?
|
Infant | 1 | 2014 | 36192 | 0.010 |
Why?
|
Brain | 1 | 2018 | 27112 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 36426 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 42230 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81525 | 0.010 |
Why?
|
Animals | 1 | 2017 | 168459 | 0.000 |
Why?
|